A component of factor VIII preparations which can be separated from factor VIII activity down modulates human monocyte functions.

No abstract is available for this paper.

• Publication year

  1987

• Venue

  Blood

• Publication date

  1987-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1182/BLOOD.V69.4.1153.1153PMID 3030465
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effect of polymeric IgG on human monocyte functions.

  1987cited by this paper
• Effect of polymeric IgG on human accessory cell function.

  1986cited by this paper
• A functional defect in the early phase of the immune response observed in patients with hemophilia A.

  1986cited by this paper
• LAV/HTLV III presence in peripheral blood lymphocytes of seropositive young hemophiliacs.

  1985cited by this paper
• Interaction of human monocytes, macrophages, and polymorphonuclear leukocytes with zymosan in vitro. Role of type 3 complement receptors and macrophage-derived complement.

  1985cited by this paper
• Inability of pasteurised factor VIII preparations to induce antibodies to HTLV-III after long-term treatment.

  1985cited by this paper
• Acquisition of antibody to lymphadenopathy-associated virus in patients with classic hemophilia (factor VIII deficiency).

  1985cited by this paper
• Complexes of IgG and Plasma Proteins in Factor VIII Preparations — a Possible Cause of Adverse Reactions

  1985cited by this paper
• Absence of antibodies to AIDS virus in haemophiliacs treated with heat-treated Factor VIII concentrate.

  1985cited by this paper
• SEROCONVERSION FOR HTLV-III SINCE 1980 IN BRITISH HAEMOPHILIACS

  1985cited by this paper
• In vitro T cell-mediated killing of Pseudomonas aeruginosa. II. The role of macrophages and T cell subsets in T cell killing.

  1985cited by this paper
• Retrovirus resembling HTLV in macrophages of patients with AIDS.

  1985cited by this paper
• Coincidental appearance of LAV/HTLV-III antibodies in hemophiliacs and the onset of the AIDS epidemic.

  1985cited by this paper
• Antibodies reactive with human T cell leukemia viruses in the serum of hemophiliacs receiving factor VIII concentrate.

  1985cited by this paper
• Unusually high incidence of tuberculosis among boys with haemophilia during an outbreak of the disease in hospital.

  1985cited by this paper
• Prevalence of antibodies to human T-lymphotropic virus-III (HTLV-III) in hemopheliacs and other patients chronically substituted with blood products

  1985cited by this paper
• Lymphadenopathy-associated virus antibodies and T cells in hemophiliacs treated with cryoprecipitate or concentrate.

  1985cited by this paper
• Suppression of the immune response to Listeria monocytogenes. I. Immune complexes inhibit resistance.

  1984cited by this paper
• Increase in prevalence of anti-HTLV-III in haemophiliacs.

  1984cited by this paper
• RECOVERY AND INACTIVATION OF INFECTIOUS RETROVIRUSES ADDED TO FACTOR VIII CONCENTRATES

  1984cited by this paper
• Recovery and inactivation of infectious retroviruses from factor VIII concentration.

  1984cited by this paper
• Characterization of blood mononuclear cells of rheumatoid arthritis patients. II. Depressed PPD presentation by monocytes to T lymphocytes.

  1983cited by this paper
• Receptors for C3b and C3bi promote phagocytosis but not the release of toxic oxygen from human phagocytes

  1983cited by this paper
• Inhibition of phagocytosis of complement C3- or immunoglobulin G-coated particles and of C3bi binding by monoclonal antibodies to a monocyte-granulocyte membrane glycoprotein (Mol).

  1983cited by this paper
• Stimulation of the intracellular killing of Staphylococcus aureus by monocytes: regulation by immunoglobulin G and complement components C3/C3b and B/Bb.

  1982cited by this paper
• Antigens on human monocytes identified by monoclonal antibodies.

  1981cited by this paper
• Hepatitis B Surface Antigen Circulating Immune Complexes (HBsAg‐CICs) in Patients with Bleeding Disorders

  1981cited by this paper
• Reversible and irreversible loss of Fc receptor function of human monocytes as a consequence of interaction with immunoglobulin G.

  1980cited by this paper
• Maturation-linked expression of C3b and C3b' receptors on developing human bone marrow and peripheral blood granulocytes.

  1979cited by this paper
• Maturation-linked expression of the Fc (IgG) receptor on developing human bone marrow and peripheral blood granulocytes.

  1979cited by this paper
• [39] The generation of chemiluminescence (CL) by phagocytic cells

  1978cited by this paper
• Immune complexes and abnormal liver function in haemophilia.

  1977cited by this paper
• Generation of superoxide anion and chemiluminescence by human monocytes during phagocytosis and on contact with surface-bound immunoglobulin G

  1976cited by this paper
• Extracellular and bacterial factors influencing staphylococcal phagocytosis and killing by human polymorphonuclear leukocytes

  1976cited by this paper
• INTERACTION OF AGGREGATED γ-GLOBULIN WITH B LYMPHOCYTES

  1972cited by this paper
• Differences in anti-protein A activity among IgG subgroups.

  1969cited by this paper
• PROPERTIES OF ANTIBODIES CYTOPHILIC FOR MACROPHAGES

  1966cited by this paper
• The Assay of Antihaemophilic‐Globulin Activity

  1955cited by this paper

• How we choose factor VIII to treat hemophilia.

  2012cites this paper
• Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response

  2007cites this paper
• Long-term surveillance studies of previously untreated and treated patients, virally uninfected and infected patients — impact on the immune and other systems

  2005cites this paper
• The Impact of a Very High Purity Factor VI11 Concentrate on the Immune System of Human Immunodeficiency Virus-Infected Hemophiliacs: A Randomized, Prospective, Two-Year Comparison With an Intermediate Purity Concentrate

  2003cites this paper
• Effect of clotting factors concentrates on lymphocyte and neutrophil function in vitro

  2003cites this paper
• Safety of the new generation recombinant factor concentrates

  2002cites this paper
• New‐generation recombinant factor concentrates: bridge to gene therapy

  2001cites this paper
• Progression to acquired immunodeficiency syndrome in 94 human immunodeficiency virus-positive hemophiliacs with long-term follow-up.

  2001cites this paper
• Immunosuppressive effects of factor IX products: an in vitro study

  1999cites this paper
• A longitudinal study of immunological status in Chinese Haemophiliacs: importance of the heat viral inactivation of factor concentrates. II. Improvements of CD4/CD8 ratio after treatments with heat‐inactivated factor concentrates

  1998cites this paper
• Clinical characteristics and blood product usage in AIDS‐associated lymphoma in haemophiliacs: a case‐control study

  1998cites this paper
• Clotting factor concentrates and immune function in haemophilic patients

  1998cites this paper
• Laboratory and clinical markers of HIV infection in a national haemophilia cohort treated with recombinant factor VIII concentrate. The Association of Hemophilia Clinic Directors of Canada.

  1998cites this paper
• Differences in Immune Response between HCV Positive, HIV Negative Haemophilia A and B Patients

  1998cites this paper
• Laboratory and clinical markers of HIV infection in a national haemophilia cohort treated with recombinant factor VIII concentrate

  1998cites this paper
• Effect of intermediate‐ and high‐purity factor VIII concentrates on immune function in HIV‐seropositive haemophiliacs as assessed by quantitative CD 4 counts

  1997cites this paper
• Measurement of anticomplementary activity in therapeutic intravenous immunoglobulin preparations.

  1997cites this paper
• Dose of non-heat-treated factor VIII concentrate and HIV-1 RNA levels.

  1997cites this paper
• Cytokine contamination of biological products.

  1997cites this paper
• Abnormal immune parameters in HIV‐seronegative haemophilic patients

  1996cites this paper
• AIDS‐associated lymphomas and other cancers in individuals with haemophilia

  1996cites this paper
• The impact of a very high‐purity factor VIII concentrate on the immune system of HIV‐infected haemophiliacs: a randomized, two‐year comparison with a high‐purity concentrate

  1996cites this paper
• An association between clotting factor concentrates use and mortality in human immunodeficiency virus-infected hemophilic patients.

  1995cites this paper
• Association of changes in monocyte antigen presentation and cytokine production in haemophilic boys with treatment and blood‐borne virus infection

  1995cites this paper
• Cytolytic activity against mycobacterial antigens: differences between haemophiliacs with and without HIV infection

  1995cites this paper
• Future perspectives in paediatric haemophilia

  1995cites this paper
• A longitudinal study of immunological status in Chinese haemophiliacs: importance of the heat viral inactivation of factor concentrates. I. Immunological associations with the consumption of factor concentrates

  1995cites this paper
• Modern treatment of haemophilia: choice of products for the treatment of haemophilia A and B

  1995cites this paper
• Immune function in patients receiving recombinant factor VIII (rFVIII, Kogenate) and other very‐high‐purity factor VIII products

  1995cites this paper
• Factor VIII concentrates and the immune system--laboratory investigations.

  1995cites this paper
• Safety of plasma derivatives.

  1994cites this paper
• High Versus Ultra-high Purity Factor VIII Concentrate Therapy: Prospective Evaluation of Immunological and Clinical Parameters in HIV Seronegative and Seropositive Hemophiliacs

  1994cites this paper
• [Blood-saving surgery].

  1994cites this paper
• Identification of transforming growth factor-beta as a contaminant in factor VIII concentrates: a possible link with immunosuppressive effects in hemophiliacs.

  1994cites this paper
• Impact of Replacement Therapy on the Evolution of HIV Infection in Hemophiliacs

  1994cites this paper
• Effect of low- and intermediate-purity clotting factor therapy on progression of human immunodeficiency virus infection in congenital clotting disorders. Transfusion Safety Study Group.

  1994cites this paper
• Separation of polysaccharide-specific human immunoglobulin G subclasses using a protein A superose column with a pH gradient elution system.

  1993cites this paper
• Modern Treatment of Hemophilia: From the Shadows Towards the Light

  1993cites this paper
• Recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion Practices Committee

  1993cites this paper
• Factor VIII:c Concentrate Virus Inactivated: Progress in Purification by Using Classic Chromatographic Methods

  1993cites this paper
• Three-year randomised study of high-purity or intermediate-purity factor VIII concentrates in symptom-free HIV-seropositive haemophiliacs: effects on immune status.

  1993cites this paper
• Immunological effects of intermediate purity clotting factor concentrates: failure to affect lymphocyte activation in vivo

  1993cites this paper
• Immunological abnormalities in haemophiliacs.

  1992cites this paper
• Immune Status of Asymptomatic HIV-Infected Hemophiliacs: Randomized, Prospective, Two-Year Comparison of Treatment with a High-Purity or an Intermediate-Purity Factor VIII Concentrate

  1992cites this paper
• Factor VIII concentrates in HIV-1-positive hemophiliacs--is pure better?

  1992cites this paper
• Faktor VIII-Behandlung bei HIV-infizierten Hämophilen: Einfluß des Konzentrattyps auf den Verlauf der HIV-Infektion

  1992cites this paper
• The impact of clotting factor concentrates on the immune system in individuals with hemophilia.

  1992cites this paper
• The impact of a very high purity factor VIII concentrate on the immune system of human immunodeficiency virus-infected hemophiliacs: a randomized, prospective, two-year comparison with an intermediate purity concentrate.

  1991cites this paper
• Progress in the Clinical Management of Haemophilia

  1991cites this paper
• Protective antibodies to hepatitis B virus in haemophiliacs

  1991cites this paper
• Consistently normal CD4+, CD8+ levels in haemophilic boys only treated with a virally safe factor VIII concentrate (BPL 8Y)

  1991cites this paper
• Effects of factor VIII concentrates on the immune system in hemophilic patients

  1991cites this paper
• The Effect of Chronic Exposure to Clotting Factor Concentrates on the Immune System

  1991cites this paper
• Coagulation and Blood Transfusion

  1991cites this paper
• Blood and blood products

  1991cites this paper
• High Molecular Weight Aggregate Content of Heated and Unheated Factor VIII Products Determined by Fast‐Protein Liquid Chromatography

  1990cites this paper
• HIV-1 infection in haemophilia.

  1990cites this paper
• Modulation of human monocyte functions by factor VIII-anti-factor VIII complexes present in an affinity-purified factor VIII product.

  1990cites this paper
• Inhibition of lymphocyte IL2‐receptor expression by factor VIII concentrate: a possible cause of immunosuppression in haemophiliacs

  1990cites this paper
• 4 HIV-1 infection in haemophilia

  1990cites this paper
• In vitro and in vivo inhibition of monocyte phagocytic function by factor VIII concentrates: correlation with concentrate purity

  1990cites this paper
• Factor VIII:C concentrate purified from plasma using monoclonal antibodies: human studies.

  1989cites this paper
• Transfusion and recipient immune function.

  1989cites this paper
• Some characteristics of aggregates of IgG and plasma proteins in heat-treated factor VIII concentrates

  1989cites this paper
• Anticardiolipin Antibodies Are Elevated in HIV-1 Infected Haemophiliacs but Do Not Predict for Disease Progression

  1989cites this paper
• [Hereditary disorders of blood coagulation with hemorrhagic diathesis].

  1989cites this paper
• Proposed Protocol for the Evaluation of the Effect of High Purity Factor Concentrates on the Immune System of Hemophilia Patients

  1989cites this paper
• Inhibition of interleuk:in‐2 secretion by factor VIII concentrates: a possible cause of immunosuppression in haemophiliacs

  1989cites this paper
• Factor concentrates for treatment of hemophilia: which one to choose?

  1989cites this paper
• Clinical Experience with Monoclate ® , a Monoclonal Antibody Purified Factor VIII Preparation from Human Plasma

  1988cites this paper
• AIDS and treatment of hemophilia patients

  1988cites this paper
• Verlaufsstudien bei nicht HIV-infizierten Patienten mit schwerer Hämophilie A und B

  1988cites this paper
• Comparable modulation of human monocyte functions by commercial factor VIII concentrates of varying purity.

  1988cites this paper
• Klinik des substitutionsbedürftigen Hämophilen bei asymptomatischem Verlauf der HIV-Infektion

  1988cites this paper
• The Impact of a Very High Purity Factor VI 11 Concentrate on the Immune System of Human Immunodeficiency Virus-Infected Hemophiliacs : A Randomized , Prospective , Two-Year Comparison With an Intermediate Purity Concentrate

  year unknowncites this paper